source
- FDA panel backs compounding of epitalon, rejects emideltide in narrow voteThe FDA advisory committee voted to allow compounding pharmacies to produce the peptide epitalon, while narrowly voting against allowing the production of emideltide. The decision follows the pane…
- Sanofi stops development of eczema drug amlitelimab after mixed trial resultsSanofi announced on Friday that it is halting further development of amlitelimab for atopic dermatitis, a drug it had once promoted as a potential successor to its blockbuster Dupixent. The compan…